Celularity
VerifiedClinical-stage biotechnology company productizing allogeneic cells and tissues derived from the postpartum placenta.
Launch date
Employees
Market cap
$64.3m
Net debt
($60.8m)
Enterprise valuation
$125m (Public information from Jul 2024)
Share price
$2.99 CELU
Florham Park New Jersey (HQ)
Deals in current and previous year:
| USD | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 49 % | (16 %) | 249 % | (69 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (458 %) | (454 %) | (785 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1458 %) | (469 %) | 79 % | - | - |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 369 % | 414 % | 436 % | - | - |
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor | $0.0 | round |
| investor | $0.0 Valuation: $0.0 87.5x EV/LTM Revenues -19.1x EV/LTM EBITDA | round | |
| investor investor investor investor | $0.0 Valuation: $0.0 87.5x EV/LTM Revenues -19.1x EV/LTM EBITDA | round | |
| investor | $0.0 | round | |
| N/A | $0.0 | round | |
| investor | $0.0 | round | |
* | $6.0m | Private Placement VC | |
| Total Funding | 000k | ||
Related Content
Recent News about Celularity
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Celularity
Edit
ACQUISITION by Celularity Aug 2018